EUCTR2007-003195-19-IE进行中（未招募）不适用
A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (> 4 cm) - IIIA Non- Small Cell Lung Cancer (NSCLC) - E1505
ICORG0 个研究点目标入组 1,500 人开始时间: 2007年6月11日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 1,500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.0 In order to be eligible for this trial, patients must have undergone complete resection of their non-small cell lung cancer (NSCLC) [stage IB (=/= 4 cm) - IIIA (T2-3N0, T1-3N1, T1-3N2) prior to enrollment. (Refer to Appendix X for staging guidelines per AJCC 6th edition). Accepted types of resection will consist of lobectomy, sleeve lobectomy, bi-lobectomy or pneumonectomy. Resections by segmentectomy or wedge resection will not be accepted. Mediastinal lymph node sampling at specified levels is required pre-operative (mediastinoscopy) or intraoperatively (level 7 and 4 for right sided tumors or level 7 and 5 and/or 6 for left sided tumors). Please refer to Section 5 for specific details on lymph node level sampling requirements and resection criteria.
- •2.0 Patients must be no less than 6 weeks (42 days) and no more (84 days) than 12 weeks post-thoracotomy at the time of randomization and must be adequately recovered from surgery.
- •3.0 Age = 18 years.
- •4.0 ECOG performance status 0 or 1.
- •5.0 Patients must not have received the following:
- •5.1 Prior systemic chemotherapy at any time. Methotrexate (MTX) given in low doses for non-malignant conditions with last dose at least 2 weeks prior to date of registration will be allowed. Other low dose chemotherapeutics for non-malignant conditions will be considered, but review by the study chair is required.
- •5.2 Hormonal cancer therapy or radiation therapy as prior cancer treatment within 5 years of randomization. (Prior surgery, biologic therapy, hormonal therapy, or radiation therapy for a malignancy over 5 years prior to enrollment that is now considered cured is acceptable.)
- •6.0 Patients must not have any history of cancer within 5 years from randomization, with the exception of in-situ carcinoma of the cervix or completely resected non-melanoma skin cancer.
- •7.0 Required laboratory values obtained within two weeks of randomization:
- •ANC = 1500 mm3
- •Platelets = 100,000/mm3
- •Prothrombin time/INR = 1.5
- •Or, if patient is on therapeutic anticoagulation, prothrombin time/INR = 3.0
- •PTT = institutional upper limit of normal (ULN) OR, if patient is on therapeutic anticoagulation, PTT must be = 1.5 x ULN
- •Total Bilirubin = 1.5 mg/dL
- •SGOT (AST) < 5 x upper limit of normal (ULN)
- •SGPT (ALT) < 5 x upper limit of normal (ULN)
- •8.0 Patients must have adequate renal function as determined by the following tests within 2 weeks prior to randomization:
- •Serum Creatinine = 1.5 x institutional upper limit of normal (ULN)
- •Urine protein should be screened by urine analysis for Urine Protein Creatinine (UPC) ratio. For UPC ratio > 0.5, 24-hour urine protein must be obtained and the level must be < 1000 mg (1g) for patient enrollment.
- •9.0 Patients with a known history of myocardial infarction or other evidence of arterial thrombotic disease (angina) will be allowed on study only if they have had no evidence of active disease for at least 12 months prior to randomization.
- •10.0 Patients with any history of cerebral vascular accident (CVA) or transient ischemic attack (TIA) will not be allowed on trial.
- •11.0 Women must not be pregnant or breast-feeding due to potential harm to the fetus or infant from cytotoxic chemotherapy and the unknown risk from bevacizumab. It is also unknown if these agents are excreted into breast milk.
- •All females of childbearing potential must have a blood or urine test within 2 weeks prior to randomization to rule out pregnancy.
- •12.0 All patients must have a documented BP
排除标准
- •1.0 Patients less than 6 weeks (42 days) and more than 12 weeks (84 days) post-thoracotomy at the time of randomization and must be adequately recovered from surgery.
- •2.0 Age = 18 years.
- •3.0 Patients who have received the following:
- •3.1 Prior systemic chemotherapy at any time. (Please refer to principal inclusion criteria 5.1 for exception)
- •3.2 Hormonal cancer therapy or radiation therapy as prior cancer treatment within 5 years of randomization. (Prior surgery, biologic therapy, hormonal therapy, or radiation therapy for a malignancy over 5 years prior to enrollment that is now considered cured is acceptable.)
- •4.0 Patients with history of cancer within 5 years from randomization, with the exception of in-situ carcinoma of the cervix or completely resected non-melanoma skin cancer.
- •5.0 Required laboratory values not obtained within two weeks of randomization
- •6.0 Inadequate renal function.
- •7.0 Evidence of active myocardial infarction or other evidence of arterial thrombotic disease (angina) within 12 months prior to randomization.
- •8.0 History of cerebral vascular accident (CVA) or transient ischemic attack (TIA).
- •9.0 Pregnant or breast-feeding women due to potential harm to the fetus or infant from cytotoxic chemotherapy and the unknown risk from bevacizumab. It is also unknown if these agents are excreted into breast milk.
- •All females of childbearing potential who have not had a blood or urine test within 2 weeks prior to randomization to rule out pregnancy.
- •10.0 Both fertile men and women not agreeing to use adequate contraceptive measures during study treatment and for at least 6 months after completion of bevacizumab.
- •11.0 Any clinically significant ongoing, active or serious infection, symptomatic or uncontrolled congestive heart failure, symptomatic or uncontrolled cardiac arrhythmia or any other medical condition or psychiatric illness/social situations that would limit compliance with study requirements.
- •12.0 History of bleeding diathesis or coagulopathy.
- •13.0 History of hypertension not well controlled (controlled BP defined as systolic < 150 and diastolic < 90 mm Hg within 28 days of registration) on a stable regimen of anti-hypertensive therapy.
- •14.0 Treatment with dipyridamole (Persantine), ticlopine (Ticlid), clopidogrel (Plavix) and/or cilostazol (Pletal). Patients must have stopped taking any of these agents at least 7 days prior to randomization.
- •15.0 Serious non-healing wound, ulcer, bone fracture, or have undergone a major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to randomization OR core biopsy within 7 days prior to randomization.
- •16.0 History of abdominal fistula, gastrointestinal perforation or intraabdominal abscess within 28 days prior to randomization.
- •17.0 Anticipated major surgical procedure(s) during the course of the study.
- •18.0 Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies.
- •19.0 Patients with ongoing post-operative hemoptysis (defined as bright red blood of ½ teaspoon or more).
- •20.0 Patients who will recieve pemetrexed/cisplatin therapy must NOT have squamous cell histology.
研究者
相似试验
已完成
不适用
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By SurgeryPER-155-08EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG),
已完成
3 期
A Randomized Phase III Trial of Adjuvant Chemotherapy with UFT following Curative Radiation Therapy for Locally Advanced Cervical CancerStage Ib2-IVa cervical cancer with Curative Radiation TherapyJPRN-UMIN000003651Gynecologic Oncology Trial and Investigation Consortium350
进行中（未招募）
不适用
A randomized phase III study of adjuvant chemotherapy in patients with completely resected Non-Small-Cell Lung Cancer and low-risk for recurrence: NVALT-8A - NVALT-8AThis is a randomized multicenter phase III study. Patient with a low SUV of the primary tumor prior to surgery will be randomised to four cycles of cisplatin-based chemotherapy or observation in a non-inferiority design.EUCTR2007-002644-21-NLMCG
已完成
3 期
A randomized phase III study of adjuvant chemotherapy with or without low-molecular weight heparin in completely resected non-small-cell lung cancer patients with high-risk for recurrence: NVALT- 8B.10038666lung cancerNon-small cell lung cancerNL-OMON35584niversitair Medisch Centrum Groningen600
尚未招募
3 期
A randomized phase III study of adjuvant chemotherapy in patients with completely resected Non-Small-Cell Lung Cancer and low risk for recurrence: NVALT-8AlungcancerNon-smal cell lung cancer10038666NL-OMON34015niversitair Medisch Centrum Groningen864